With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma||Beckman Research Institute of City of Hope / Margarita Gutova, MD||Reach Grants||2013||California|
|Targeting PLK1 as a Common Mechanism in Ph-like ALL||University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD||Reach Grants||2016||Texas|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|
|DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Reach Grants||2016||Pennsylvania|
|Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma||Children's Hospital of Philadelphia / John Maris, MD||Reach Grants||2016||Pennsylvania|
|Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor||Baylor College of Medicine / William Decker, PhD||Reach Grants||2013||Texas|
|Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma||The Johns Hopkins University School of Medicine / David Loeb, MD, PhD||Reach Grants||2013||Maryland|
|Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma||Duke University Medical Center / Gerard Blobe, MD, PhD||Reach Grants||2013||North Carolina|
|B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers||University of Texas Southwestern Medical Center / James Amatruda, MD, PhD||Reach Grants||2013||Texas|
|Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition||Children's Hospital of Philadelphia / Yael Mossé, MD||Reach Grants||2013||Pennsylvania|